Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,297Revenue (TTM) $M751Net Margin (%)9.7Altman Z-Score2.4
Enterprise Value $M1,392EPS (TTM) $1.0Operating Margin %13.0Piotroski F-Score4
P/E(ttm)18.2Beneish M-Score-2.9Pre-tax Margin (%)12.8Higher ROA y-yN
Price/Book1.710-y EBITDA Growth Rate %--Quick Ratio3.5Cash flow > EarningsY
Price/Sales1.75-y EBITDA Growth Rate %6.2Current Ratio4.1Lower Leverage y-yN
Price/Free Cash Flow12.4y-y EBITDA Growth Rate %-26.3ROA % (ttm)7.1Higher Current Ratio y-yN
Dividend Yield %--PEG2.8ROE % (ttm)9.7Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M68.1ROIC % (ttm)10.9Gross Margin Increase y-yN

Gurus Latest Trades with MYGN

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

MYGN is held by these investors:



MYGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HENDERSON JOHN TDirector 2017-02-23Buy6,000$18.66-2.04view
HENDERSON JOHN TDirector 2016-09-12Sell30,000$20.49-10.79view
Capone Mark ChristopherPresident & C.E.O. 2016-08-19Buy10,000$21.24-13.94view
McDade Ralph LPresident Myriad RBM, Inc. 2016-08-12Buy1,000$21.49-14.94view
Ford AlexanderPresident, MGL 2016-06-21Sell18,637$30.87-40.78view
King Gary A.Exec. VP International Ops 2016-04-06Sell15,000$39.03-53.16view
King Gary A.Exec. VP International Ops 2016-04-01Sell15,000$38.12-52.05view
GILBERT WALTER PHDDirector 2015-12-11Sell5,000$42.23-56.71view
Phanstiel S. LouiseDirector 2015-12-08Sell5,000$44-58.45view
DREISMANN HEINRICHDirector 2015-11-05Sell60,000$44.44-58.87view

Press Releases about MYGN :

Quarterly/Annual Reports about MYGN:

News about MYGN:

Articles On GuruFocus.com
Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test Apr 27 2017 
Myriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017 Apr 18 2017 
Study Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Comm Apr 17 2017 
7 of the Worst-Performing Stocks in Gurus' Portfolios Apr 07 2017 
Myriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene†Apr 06 2017 
Pivotal Study Results for Myriad’s myPath® Melanoma Test Highlighted In Two Additional Scie Apr 05 2017 
Myriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical Gene Mar 20 2017 
Myriad Genetics Launches the EndoPredict® Test in the United States for Patients with Breast Canc Mar 13 2017 
Casualty List Has Done Well; Here’s the Latest Jan 18 2017 
Industrial Companies Showing Good Potential for 2017 Jan 04 2017 

More From Other Websites
Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test... Apr 27 2017
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings? Apr 24 2017
Myriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017 Apr 18 2017
Myriad Genetics, Inc. – Value Analysis (NASDAQ:MYGN) : April 17, 2017 Apr 17 2017
Study Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A... Apr 17 2017
Myriad Genetics, Inc. breached its 50 day moving average in a Bearish Manner : MYGN-US : April 13,... Apr 13 2017
Myriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene’s... Apr 06 2017
Pivotal Study Results for Myriad’s myPath® Melanoma Test Highlighted In Two Additional Scientific... Apr 05 2017
Myriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical... Mar 20 2017
Myriad Genetics (MYGN) Launches EndoPredict Test in the US Mar 14 2017
Myriad Genetics Launches the EndoPredict® Test in the United States for Patients with Breast Cancer Mar 13 2017
Better Buy: Myriad Genetics, Inc. vs. Opko Health, Inc. Mar 11 2017
Why Is Myriad Genetics (MYGN) Up 15.8% Since the Last Earnings Report? Mar 10 2017
Bullish and Bearish Reversals in the Market Feb 27 2017
Post Earnings Coverage as Myriad's Q2 Top-line Grew 2%; Topped Estimates Feb 27 2017
GeneSight® Psychotropic Test Demonstrated Substantial Cost Savings for Payers in New Study... Feb 23 2017
Myriad’s BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with... Feb 17 2017
Myriad’s Prolaris® Test Significantly Improves the Risk Classification for One Third of Men... Feb 17 2017
Here's Why Invitae Stock Jumped as Much as 16.3% This Morning Feb 14 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)